Akebia Therapeutics, Inc. (AKBA) Income Statement
AKBA 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsAKBA revenue and net income
Where AKBA's revenue goes
2025Each bar shows an amount and its share of revenue. AKBA kept −2.3% of revenue as net income.
AKBA profit margins
AKBA growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +47.5% | −6.9% | −4.4% | — |
| Gross profit | +102.8% | −10.0% | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
AKBA quarterly EPS vs estimates
Akebia Therapeutics beat the analyst EPS estimate in 4 of the last 8 quarters. Next report: November 9, 2026 (estimate $-0.03).
AKBA income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $236.2M | $160.2M | $194.6M | $292.5M | $213.6M | $295.3M | $335.0M | $207.7M | $178.0M | $1.5M |
| Cost of revenue | $39.5M | $63.2M | $74.1M | $22.5M | $153.4M | $295.9M | $145.3M | $7.7M | $617,000 | $115.8M |
| Gross profit | $196.7M | $97.0M | $120.5M | $270.0M | $60.2M | −$601,000 | $189.7M | $200.1M | $177.4M | −$114.2M |
| Research & development | $62.4M | $37.7M | $63.1M | $166.0M | $147.9M | $218.5M | $323.0M | $291.1M | $230.9M | $115.8M |
| Sales, general & admin | $107.5M | $106.5M | $103.5M | $138.6M | $177.7M | $157.4M | $153.0M | $87.1M | $27.0M | $22.2M |
| Total operating expenses | $173.2M | $147.5M | $166.7M | $350.8M | $325.5M | $375.8M | $476.0M | $378.2M | $257.9M | $138.0M |
| Operating income | $23.5M | −$50.5M | −$46.3M | −$80.8M | −$265.3M | −$376.4M | −$286.3M | −$178.1M | −$79.9M | −$136.5M |
| Interest income | — | — | — | — | — | — | $792,000 | $6.2M | $2.8M | $901,000 |
| Interest expense | $24.2M | $18.2M | $6.0M | $15.7M | $19.9M | $8.9M | $38.6M | $6.2M | $2.8M | $901,000 |
| Income before taxes | −$3.7M | −$69.4M | −$51.9M | −$94.2M | −$282.8M | −$383.5M | −$286.3M | −$171.9M | −$76.9M | −$135.7M |
| Income taxes | $1.6M | — | $41.7M | $13.4M | −$38.0M | −$33.6M | −$6.6M | −$28.3M | −$2.8M | −$901,000 |
| Net income | −$5.3M | −$69.4M | −$51.9M | −$94.2M | −$244.9M | −$349.9M | −$279.7M | −$171.9M | −$76.9M | −$135.7M |
| EBITDA | $21.7M | −$13.7M | −$8.3M | $3.1M | −$227.3M | −$342.9M | −$247.6M | −$175.7M | −$76.1M | −$136.2M |
| EPS (diluted) | $0.00 | −$0.32 | −$0.28 | −$0.45 | −$1.70 | −$1.93 | −$2.36 | −$2.47 | −$1.92 | −$3.60 |
| Gross margin | 83.3% | 60.6% | 61.9% | 92.3% | 28.2% | −0.2% | 56.6% | 96.3% | 99.7% | −7,443.0% |
| Operating margin | 9.9% | −31.5% | −23.8% | −27.6% | −124.2% | −127.5% | −85.5% | −85.8% | −44.9% | −8,889.9% |
| Net margin | −2.3% | −43.3% | −26.7% | −32.2% | −114.7% | −118.5% | −83.5% | −82.7% | −43.2% | −8,843.5% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $49.1M | $53.5M | $57.6M | $58.8M | $62.5M | $57.3M | $46.5M | $37.4M | $43.6M | $32.6M | $56.2M | $42.0M |
| Cost of revenue | $10.4M | $12.6M | $12.2M | $9.7M | $9.9M | $7.6M | $20.4M | $14.2M | $8.3M | $2.7M | $18.7M | $18.0M |
| Gross profit | $38.7M | $40.9M | $45.4M | $49.1M | $52.6M | $49.7M | $26.1M | $23.3M | $35.4M | $29.9M | $37.5M | $24.0M |
| Research & development | $14.1M | $14.8M | $26.6M | $14.6M | $11.0M | $9.8M | $11.8M | $8.5M | $7.6M | $9.7M | $9.9M | $13.3M |
| Sales, general & admin | $28.2M | $30.4M | $26.1M | $29.1M | $26.6M | $25.7M | $27.7M | $26.5M | $26.9M | $25.4M | $26.3M | $22.7M |
| Total operating expenses | $45.0M | $45.6M | $54.0M | $44.6M | $38.5M | $36.2M | $40.4M | $35.8M | $44.1M | $44.8M | $36.2M | $37.1M |
| Operating income | −$6.3M | −$4.7M | −$8.6M | $4.4M | $14.1M | $13.5M | −$14.3M | −$12.5M | −$8.7M | −$14.9M | $1.4M | −$13.0M |
| Interest expense | $3.1M | $4.7M | $4.8M | $4.7M | $6.8M | $7.8M | $6.9M | $6.7M | $2.1M | $2.5M | $1.4M | $1.4M |
| Income before taxes | −$8.8M | −$8.9M | −$11.2M | $1.2M | $247,000 | $6.1M | −$22.8M | −$20.0M | −$8.6M | −$18.0M | $614,000 | −$14.5M |
| Income taxes | $70,000 | $126,000 | $1.0M | $615,000 | — | — | — | — | — | $9.3M | −$1,000 | $1.4M |
| Net income | −$8.9M | −$9.1M | −$12.2M | $540,000 | $247,000 | $6.1M | −$22.8M | −$20.0M | −$8.6M | −$18.0M | $614,000 | −$14.5M |
| EBITDA | −$5.2M | −$13.3M | −$6.1M | $6.2M | $7.4M | $14.2M | −$6.6M | −$4.0M | $1.2M | −$4.9M | $11.4M | −$3.7M |
| EPS (diluted) | −$0.02 | −$0.03 | −$0.05 | $0.00 | $0.03 | $0.02 | −$0.10 | −$0.10 | −$0.04 | −$0.08 | $0.00 | −$0.08 |
| Gross margin | 78.8% | 76.4% | 78.8% | 83.5% | 84.1% | 86.7% | 56.2% | 62.2% | 81.0% | 91.7% | 66.8% | 57.2% |
| Operating margin | −12.9% | −8.8% | −14.8% | 7.6% | 22.6% | 23.6% | −30.8% | −33.4% | −20.0% | −45.8% | 2.4% | −31.0% |
| Net margin | −18.1% | −16.9% | −21.2% | 0.9% | 0.4% | 10.7% | −49.0% | −53.5% | −19.7% | −55.2% | 1.1% | −34.5% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in AKBA's financial statements (latest annual report filed February 26, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
AKBA financial results
In fiscal year 2025 (ended December 31, 2025), Akebia Therapeutics reported revenue of $236.2 million, up 47.5% from the year before. It had a net loss of $5.3 million, a net profit margin of −2.3%. Diluted earnings per share came to $0.00. Over five years revenue grew at an average rate of −4.4% a year.
See the AKBA stock overview for the latest quote and news, or the AKBA chart for price history and technical indicators.
AKBA income statement FAQ
What is Akebia Therapeutics's annual revenue?
Akebia Therapeutics reported total revenue of $236.2 million for fiscal year 2025, which ended on December 31, 2025. That was up 47.5% from $160.2 million the previous year.
Is Akebia Therapeutics profitable?
No. Akebia Therapeutics reported a net loss of $5.3 million in fiscal 2025, a net profit margin of −2.3%; its operating margin was 9.9%.
What is Akebia Therapeutics's gross margin?
Akebia Therapeutics's gross margin was 83.3% in fiscal 2025: for every $100 of revenue, Akebia Therapeutics kept $83 after the direct cost of its products and services.
How much does Akebia Therapeutics spend on research and development?
Akebia Therapeutics spent $62.4 million on research and development in fiscal 2025, 26.4% of revenue.
How fast is Akebia Therapeutics growing?
Revenue grew −4.4% a year on average over the last five fiscal years, from $295.3 million to $236.2 million.
What are Akebia Therapeutics's earnings per share?
Akebia Therapeutics earned $-0.00 per diluted share in fiscal 2025, compared with $-0.32 a year earlier.
When will Akebia Therapeutics report its next earnings?
Akebia Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 9, 2026 after the market closes.
When does Akebia Therapeutics's fiscal year end?
Akebia Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on February 26, 2026.